LANREOTIDE ACETATE

Product Showcase

Information

Target Indication: Acromegaly Gastroenteropancreatic Neuroendocrine Tumors Carcinoid Syndrome  Strength:60mg, 90mg, 120mg  Formulation:Injection/PFS Timetable: Process Validation in Q3. 2026 ANDA will be submitted in Q2. 2027 in US
Chengdu Brilliant Biopharmaceutical Co.,LtdF21Chengdu Brilliant Pharmaceutical is a high-tech enterprise that engages in R&D, manufacturing and sales of therapeutic drugs. Covering API, high-end generic drugs, innovative drugs and novel drug delivery system, thus realizing comprehensive pharmaceutical industry chain layout from intermediates (INT), API and FDF, which covers small molecule(include nuclide drugs) , biological drugs and Chinese Patent Medicine.